Amílcar Falcão

ORCID iD
https://orcid.org/0000-0002-3854-6549
  • Also known as
  • Show details Hide details
A. Falcao,

Sources:
Amílcar Falcão (2015-10-03)

A. Falcão,

Sources:
Amílcar Falcão (2015-10-03)

A.C. Falcao,

Sources:
Amílcar Falcão (2015-10-03)

Amílcar Celta Falcão,

Sources:
Amílcar Falcão (2015-10-03)

Falcao A.,

Sources:
Amílcar Falcão (2015-10-03)

Falcão A.,

Sources:
Amílcar Falcão (2015-10-03)

Falcão A.C.

Sources:
Amílcar Falcão (2015-10-03)

  • Keywords
  • Show details Hide details
Pharmacology,

Sources:
Amílcar Falcão (2014-01-14)

Pharmacometrics

Sources:
Amílcar Falcão (2014-01-14)

  • Other IDs
  • Show details Hide details
ResearcherID: G-6611-2013

Sources:
ResearcherID (2013-06-29)

Scopus Author ID: 25639474900

Sources:
Scopus - Elsevier (2014-06-07)

Biography

Amilcar Falcão graduated in Pharmaceutical Sciences at the University of Coimbra, where he also obtained his PhD and his Aggregation with Specialization in Pharmacology. He is Full Professor, Director of the Institute for Interdisciplinary Research, and accumulates the functions of Vice-Rector of the University of Coimbra in the area of Research & Innovation. He was (until the end of 2017) Senior Researcher at the Center for Neuroscience and Cell Biology (CNC) and leader of the Pharmacometrics group. His extensive scientific production comprises more then 400 publications (among articles, book chapters and abstracts in refereed journals) and many scientific papers, posters and oral presentations (dozens of them by invitation), having the overwhelming majority been international and referee submitted. He supervised 16 master and 12 PhD theses. He is a regularly invited reviewer and member of the editorial board of several scientific journals. He has been several times distinguished with national and international awards, which reinforces the visibility and quality of his work throughout his career. Keeping a strong connection with the pharmaceutical industry along his career, the collaboration with the laboratories BIAL (Portugal) shall be highlighted, where he actively and significantly participates in his program of new drugs development. His contribution lies both in clinical and non-clinical testing (biostatistics, pharmacokinetics and pharmacodynamics), having been involved in over a hundred studies in total. His portfolio includes a set of molecules with particular emphasis to eslicarbazepine acetate(anti-epileptic drug) , which was the first Portuguese commercialized drug (Zebinix ®), and more recently, opicapone (a new drug for Parkinson's disease), the second Portuguese commercialized drug (Ongentys ®) . He is also Technical Director of the company ICNAS Produção (a company 100% owned by the University of Coimbra), and participated actively in obtaining the first radiopharmaceutical developed and registered in Portugal (fludeoxyglucose [18F] UC).
  • : , ,

    {{group.getActive().startDate.year}}-{{group.getActive().startDate.month}}-{{group.getActive().startDate.day}} to present {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} |  ()
    • Show Details Hide Details
    Organization identifiers
    {{group.getActive().orgDisambiguatedName}}: {{group.getActive().orgDisambiguatedCity}}, {{group.getActive().orgDisambiguatedRegion}}, {{group.getActive().orgDisambiguatedCountry}}
    Other organization identifiers provided by {{group.getActive().disambiguationSource.value}}
    • {{orgDisambiguatedExternalIdentifier.identifierType}}: {{orgDisambiguatedExternalIdentifier.preferred}} (preferred), {{orgDisambiguatedExternalIdentifierAll}}{{$last ? '' : ', '}}
    Created
    Source: {{(group.getActive().sourceName == null || group.getActive().sourceName == '') ? group.getActive().source : group.getActive().sourceName}}
No education added yet
  • : , ,

    {{group.getActive().startDate.year}}-{{group.getActive().startDate.month}}-{{group.getActive().startDate.day}} to present {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} |  ()
    • Show Details Hide Details
    Organization identifiers
    {{group.getActive().orgDisambiguatedName}}: {{group.getActive().orgDisambiguatedCity}}, {{group.getActive().orgDisambiguatedRegion}}, {{group.getActive().orgDisambiguatedCountry}}
    Other organization identifiers provided by {{group.getActive().disambiguationSource.value}}
    • {{orgDisambiguatedExternalIdentifier.identifierType}}: {{orgDisambiguatedExternalIdentifier.preferred}} (preferred), {{orgDisambiguatedExternalIdentifierAll}}{{$last ? '' : ', '}}
    Created
    Source: {{(group.getActive().sourceName == null || group.getActive().sourceName == '') ? group.getActive().source : group.getActive().sourceName}}
No employment added yet
No publications added yet